Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin

Oncogene

Volumn 34, Issue 14, 2014, Pages 1843-1852

  Moti, N ^a   Malcolm, T ^a   Hamoudi, R ^a,k   Mian, S ^a   Garland, G ^b   Hook, C E ^c   Burke, G A A ^c   Wasik, M A ^d   Merkel, O ^e,f   Kenner, L ^f,g,h   Laurenti, E ^i,j   Dick, J E ^i,j   Turner, S D ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF HAIL   (Saudi Arabia)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f European Research Initiative on ALK related Malignancies (ERIA)   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CRIZOTINIB; ETOPOSIDE; NUCLEAR PROTEIN; NUCLEOPHOSMIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; C57BL MOUSE; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CYTOLOGY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; LARGE CELL LYMPHOMA; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; PLURIPOTENT STEM CELL; PRESCHOOL CHILD; SIDE POPULATION CELL; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; ETOPOSIDE; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PLURIPOTENT STEM CELLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIDE-POPULATION CELLS; SIGNAL TRANSDUCTION;

EID: 84899780589     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.112     Document Type: Article

References (41)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
2. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
3. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
4. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
5. Cobaleda C, Jochum W, Busslinger M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 2007; 449: 473-477.
6. Visvader JE. Cells of origin in cancer. Nature 2011; 469: 314-322.
7. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
8. Turner SD, Alexander DR. Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells. Leukemia 2006; 20: 572-582.
9. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003; 101: 1919-1927.
10. Jager R, Hahne J, Jacob A, Egert A, Schenkel J, Wernert N et al. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. Anticancer Res 2005; 25: 3191-3196.
11. Turner SD, Merz H, Yeung D, Alexander DR. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. Anticancer Res 2006; 26: 3275-3279.
12. Turner SD, Tooze R, Maclennan K, Alexander DR. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 2003; 22: 7750-7761.
13. Turner SD, Alexander DR. What have we learnt from mouse models of NPM-ALKinduced lymphomagenesis? Leukemia 2005; 19: 1128-1134.
14. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797-1806.
15. Golebiewska A, Brons NH, Bjerkvig R, Niclou SP. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 2011; 8: 136-147.
16. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70-78.
17. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
18. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317: 337.
19. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer The. 2007; 6(12 Pt 1): 3314-3322.
20. Georgantas RW3rd, Tanadve V, Malehorn M, Heimfeld S, Chen C, Carr L et al. Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res 2004; 64: 4434-4441.
21. Doulatov S, Notta F, Eppert K, Nguyen LT, Ohashi PS, Dick JE. Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat Immunol 2010; 11: 585-593.
22. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 2011; 333: 218-221.
23. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-4807.
24. Wang X, Werneck MB, Wilson BG, Kim HJ, Kluk MJ, Thom CS et al. TCR-dependent transformation of mature memory phenotype T cells in mice. J Clin Invest 2011; 121: 3834-3845.
25. Gibbs KDJr., Jager A, Crespo O, Goltsev Y, Trejo A, Richard CE et al. Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML. Cell Stem Cell 2012; 10: 210-217.
26. Gelebart P, Hegazy SA, Wang P, Bone KM, Anand M, Sharon D et al. Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma. Blood Cancer J 2012; 2: e82.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011; 144(5): 646-674.
28. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998; 91: 2076-2084.
29. Swerdlow, SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, 2008. p 439.
30. Pearson JD, Lee JK, Bacani JT, Lai R, Ingham RJ. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma. Int J Clin Exp Pathol 2011; 4: 124-133.
31. Laurent C, Lopez C, Desjobert C, Berrebi A, Damm-Welk C, Delsol G et al. Circulating t(2;5)-positive cells can be detected in cord blood of healthy newborns. Leukemia 2012; 26: 188-190.
32. Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010; 28: 3987-3993.
33. Mussolin L, Damm-Welk C, Pillon M, Zimmermann M, Franceschetto G, Pulford K et al. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia 2012; 27: 416-422.
34. Mussolin L, Pillon M, d'Amore ES, Santoro N, Lombardi A, Fagioli F et al. Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma. Leukemia 2005; 19: 1643-1647.
35. Lutz C, Woll PS, Hall G, Castor A, Dreau H, Cazzaniga G et al. Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia. Leukemia 2013; 27: 1204-1207.
36. Cui YX, Kerby A, McDuff FK, Ye H, Turner SD. NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner. Blood 2009; 113: 5217-5227.
37. del Mistro A, Leszl A, Bertorelle R, Calabro ML, Panozzo M, Menin C et al. A CD30-positive T cell line established from an aggressive anaplastic large cell lymphoma, originally diagnosed as Hodgkin's disease. Leukemia 1994; 8: 1214-1219.
38. Goodell M.A. Multipotential stem cells and 'side population' cells. Cytotherapy 2002; 4: 507-508.
39. Goodell M.A. Stem cell identification and sorting using the Hoechst 33342 side population (SP). Curr Protoc Cytom 2005; Chapter 9: Unit9 18.
40. Goodell MA, McKinney-Freeman S, Camargo FD. Isolation and characterization of side population cells. Methods Mol Biol 2005; 290: 343-352.
41. Marko NF, Frank B, Quackenbush J, Lee NH. A robust method for the amplification of RNA in the sense orientation. BMC Genomic 2005; 6: 27.